SR141716, Rimonabant, to reduce alcohol consumption

SR141716，利莫那班，减少酒精消耗

• 批准号: 7146650
• 负责人: David T George
• 金额: --
• 依托单位: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7146650
• 关键词: alcoholic beverage consumption; alcoholism /alcohol abuse; alcoholism /alcohol abuse chemotherapy; alcoholism antagonist; breath tests; cannabinoid receptor; clinical trials; human subject; human therapy evaluation; inhibitor /antagonist; patient oriented research

Rimonabant is a CB1 cannabinoid receptor antagonist which has been shown in animals to reduce alcohol consumption. This protocol is intended to determine if Rimonabant will decrease alcohol consumption in individuals who consume between 20 and 50 drinks of alcohol per week. To date, twenty participants have been enrolled in this double-blind study. Data analysis will not be preformed until the study is complete.

利莫那班是一种CB1大麻素受体拮抗剂，已在动物中显示可减少酒精消耗。该方案旨在确定利莫那班是否会减少每周饮酒20至50杯的个体的饮酒量。到目前为止，已有20名参与者参加了这项双盲研究。在研究完成之前，不会进行数据分析。